Of course, they cite Ariad as having spent $444M to create "1" new drug -- I'll assume this is Iclusig.
What this analysis leaves out is the parade of indications, which is to say that calling Iclusig "one drug" in the way DNDN's drug was "one drug" is a bit of a misnomer.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.